Use of strong opioids in advanced cancer pain: a randomized trial Franco Marinangeli, MD, Alessandra Ciccozzi, MD, Marco Leonardis, MD, Luca Aloisio, MD, Anna Mazzei, MD, Antonella Paladini, MD, Giampiero Porzio, MD, Paolo Marchetti, MD, Giustino Varrassi, MD  Journal of Pain and Symptom Management  Volume 27, Issue 5, Pages 409-416 (May 2004) DOI: 10.1016/j.jpainsymman.2003.10.006

Fig. 1 Percent of cumulative weeks that the patient defined treatment as “satisfactory” ∗P=0.041, and percent of cumulative weeks with no changes in therapy. ∗∗P=0.001 Group B versus Group A. Journal of Pain and Symptom Management 2004 27, 409-416DOI: (10.1016/j.jpainsymman.2003.10.006)

Fig. 2 Mean visual analogue scale scores (VAS) of pain intensity reported by the patient and general condition reported by the patient's relative in the week preceding and subsequent to a change in therapy. Note that a higher value in VAS for pain denotes increased pain, whereas a higher value for the general condition denotes improvement. ∗P=0.0001 versus previous week; †P=0.0001 versus Group A. Journal of Pain and Symptom Management 2004 27, 409-416DOI: (10.1016/j.jpainsymman.2003.10.006)